BC Innovations | Oct 20, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) Mouse and cell culture studies suggest inhibiting APOBEC3G could help...
BC Innovations | May 27, 2010
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G; A3G); IL-15; toll-like receptor 2 (TLR2); TLR3; TLR9 A study in rhesus macaques suggests...
BC Innovations | Oct 9, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Virion infectivity factor (Vif) A screening study identified a small molecule Vif inhibitor that may be useful for...
BC Innovations | Apr 10, 2008
Targets & Mechanisms

Putting Cancer to REST

Although previous work has shown that either increasing or decreasing the level of repressor element-1-silencing transcription factor can induce tumors, it was unclear how to go about targeting or modulating the zinc-finger DNA-binding protein. Two...
BioCentury | Apr 9, 2007
Tools & Techniques

Unraveling ubiquitin complexity

Like kinases, ligases are a ripe target area. The difference is that ligases generally are harder to inhibit. Rigel Inc. thinks it achieved proof of principle in the ubiquitin ligase field for cancer a few...
Items per page:
1 - 5 of 5